{"id":"BILL-s1458","name":"Health Legislation Amendment (Improved Medicare Integrity and Other Measures) Bill 2025","slug":"health-legislation-amendment-improved-medicare-integrity-and-other-measures-bill-2025","collection":"bill","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":446016,"registerId":"commonwealth-BILL-s1458-current","compilationNumber":null,"startDate":"2026-05-05","status":"royal_assent","reasons":null,"registeredAt":null},"sections":[],"analysis":{"summary":{"status_summary":"The bill received royal assent on 4 September 2025 and is now Act No. 38 of 2025.","complexity_score":7,"likely_questions":["When do the reduced claim timeframes for Medicare and dental services begin to apply?","How do the new pharmacy approval time limits and repeat request rules affect pending applications?"],"complexity_factors":["Multiple schedules amending six separate Acts","Contingent commencement provisions linked to another Act","New criminal offences, civil penalties and recovery mechanisms"],"plain_english_summary":"The Act tightens Medicare and dental claim timeframes (reducing lodging periods from two years to one year for services on/after 5 Sept 2025), strengthens fraud and warrant powers, and streamlines pharmacy approval timing. It also tightens rules and penalties for therapeutic goods and vaping products, including new offences and enforcement tools.\n\nThese changes affect medical practitioners, dentists, pharmacists, suppliers of therapeutic and vaping goods, and patients claiming benefits — altering compliance, enforcement risks and administrative deadlines."},"flash_summary":{"complexity_score":8,"scope_assessment":{"changed":true,"description":"Yes. The Act goes beyond a narrow \"Medicare integrity\" package by bundling extensive Therapeutic Goods Act and Public Health (Tobacco and Other Products) Act amendments. In addition to tightening Medicare claim timeframes, recovery and information powers (Schedules 1 and 4), the Act: brings vaping goods explicitly into TGA regulation and advertising controls; creates new criminal and civil penalties for breaching conditions of therapeutic exemptions/approvals/authorities (new ss 32CP/32CQ); alters enforcement, delegation and seizure procedures; and adds transitional phasing rules for tobacco packaging. Those TGA and tobacco measures materially broaden the regulatory subject matter and enforcement scope compared with what a narrowly focused Medicare‑integrity bill would contain (see Schedule 2 and Schedule 3)."},"complexity_factors":["Amends multiple principal Acts across health law (at least six separate Acts: Dental Benefits Act 2008; Health Insurance Act 1973; Human Services (Medicare) Act 1973; National Health Act 1953; Therapeutic Goods Act 1989; Public Health (Tobacco and Other Products) Act 2023).","Many discrete schedules and parts (Schedules 1–4) with internal divisions and staged commencements (conditional on other legislation commencing).","Introduction of new criminal offences and civil penalties (Therapeutic Goods Act new ss 32CP/32CQ) with high penalties and strict liability tiers, plus cross‑references to offences in the Criminal Code and Crimes Act (Schedule 2, Part 7; Schedule 1, Part 2).","New administrative powers with procedural safeguards and time limits (e.g. new notice power 129AACA with 21‑day minimum; recovery provisions 129AAK), plus strict liability and civil penalty overlays (Schedule 4, Part 1).","Substantial cross‑referencing between Acts and internal sections (e.g. bringing vaping goods into numerous TGA provisions, linking Therapeutic Goods advertising rules with the Public Health (Tobacco) Act).","New 'persons assisting' regime for authorised officers and associated changes to warrant and entry powers (Schedule 2, Part 2), increasing layered powers and delegation rules.","Addition of transitional and saving provisions and a delegated power for the Minister to make transitional rules (Schedule 4, Part 3), which creates conditional implementation complexity.","Regulatory dependence: several items rely on delegated regulations (fees to be prescribed; authorisations under s 42DZC; phasing‑in/out by later regulations), so practical effect depends on subordinate instruments.","Removal and replacement of review pathways and amendments to judicial/tribunal review provisions (Schedule 2, Part 8), creating legal‑process complexity for affected parties."],"plain_english_summary":"**What this law changes (mechanically)\n\n- Shorter claim window for bulk‑billed services: The time limit to make claims for bulk‑billed dental and Medicare services is reduced from 2 years to 1 year (Dental Benefits Act 2008; Health Insurance Act 1973). (Schedule 1, Part 1: items 1–8)\n\n- Stronger Medicare investigative and recovery powers: The Act revises the definition of what counts as a \"relevant offence\" involving Medicare/dental/pharmaceutical claims; it expands departmental investigative tools (including evidence handling rules) and creates a clear statutory route to recover overpayments as debts. It also creates a new notice power allowing Chief Executive Medicare to require people to give information or documents (with a minimum 21‑day compliance period) and attaches strict liability and civil penalties for non‑compliance. (Schedule 1, Part 2: item 9; Schedule 4, Part 1: items 1–2, 3–10)\n\n- Changes to pharmacist approval processes: Timeframes and procedures for requests to the Minister about pharmacy approvals are altered (Minister must decide or be taken to have decided within 4 months of a request; limits on repeat requests for the same premises — 12 months between requests; and procedural changes for notices). (Schedule 1, Part 3: items 14–23)\n\n- Therapeutic Goods Act changes (big package): Vaping goods are brought explicitly within the Therapeutic Goods Act framework in several places; additional enforcement tools and procedural changes are added (authorised persons may use assistants; broadened grounds and notice requirements for enforceable directions; delegation of certain powers; expanded definitions and tests for shortages so foreseeable shortages count; fees must be paid before some consents will be considered). The Act also creates new criminal offences and civil penalties for breaching conditions of exemptions, approvals or authorities relating to therapeutic goods (new sections 32CP and 32CQ). (Schedule 2, Parts 1–9: many items; see particularly Part 7 items 78–80)\n\n- Advertising and tobacco law tweaks: The Public Health (Tobacco and Other Products) Act is adjusted so that advertisements for e‑cigarette products that are regulated by the Therapeutic Goods Act may be treated under the TGA rules; the Act also adds rules allowing later regulations to phase‑in or phase‑out product packaging, warnings and other appearance requirements. (Schedule 3, Parts 1 and 3: items 1–5, 9–14)\n\n- Additional technical and review changes: The Act alters some review and transitional processes (for example, how certain TGA review pathways operate and saving provisions for applications in progress), and allows the regulations to adopt external instruments by reference. (Schedule 2, Parts 8–9, and Schedule 4, Part 3)\n\nWho is affected\n\n- Medical and dental practitioners, and pharmacies: shorter claim windows and strengthened recovery powers mean these providers bear more timing and documentation risk, and may face faster debt recovery if claims are incorrect. (Schedule 1; Schedule 4)\n\n- Pharmacists seeking approvals: changes to decision timeframes and limits on re‑applications affect the administrative pathway and commercial timing for pharmacy supply of pharmaceutical benefits. (Schedule 1, Part 3)\n\n- Therapeutic goods and vaping manufacturers, importers, suppliers and advertisers: bringing vaping goods explicitly into the Therapeutic Goods Act, adding criminal and civil penalties for breaching conditions of exemptions/approvals/authorities, and new enforcement powers increase compliance obligations and legal risk. (Schedule 2, Part 1 and Part 7)\n\n- Publishers, advertisers and those handling e‑cigarette marketing: advertising exemptions and cross‑references between the TGA and the Public Health (Tobacco and Other Products) Act change which rules apply and where authorisations are required. (Schedule 3, Part 1)\n\n- Individuals and third parties from whom Medicare may seek documents or information: Chief Executive Medicare gains a formal notice power requiring production of relevant material; failure to comply carries a strict liability offence and civil penalties. (Schedule 4, Part 1: new section 129AACA and 129AACB)\n\nWhy the government says it matters (official purpose claims)\n\n- The stated aims are: to improve Medicare integrity (reduce fraud, recover erroneous payments), to streamline and clarify pharmacy approval processes, to equip the department to manage therapeutic goods shortages, and to strengthen enforcement against unlawful therapeutic and vaping goods, including clearer controls on advertising.\n\nTesting those claims against costs, incentives and trade‑offs (practical impacts and risks)\n\n- Who pays and who benefits: The immediate fiscal beneficiary is the Commonwealth (improved ability to recover overpayments and deter fraud). Costs fall in concentrated ways on regulated parties: medical/dental providers (who must lodge claims faster and keep records aligned to shorter deadlines), pharmacists (who face new administrative timing rules), and therapeutic/goods/vaping businesses (who face higher compliance costs, fees and criminal/civil risk). The Act creates a direct enforcement incentive for the regulator to pursue recoveries and compliance actions (Schedule 4: 129AAK and related recovery provisions).\n\n- Compliance burden: New criminal penalties (up to 5 years and large penalty units for some therapeutic goods breaches — Schedule 2, Part 7: new section 32CP) and civil penalties raise compliance costs for manufacturers, sponsors and suppliers. Requiring payment of prescribed fees before processing consents (Schedule 2, Part 9 items 86–91) shifts processing costs onto applicants and may reduce the regulator’s processing load but raises barriers (and cash flow costs) for smaller operators.\n\n- Bureaucratic discretion and decision‑making: Several provisions broaden Secretary/Minister discretion — e.g. enforceable directions must be given where \"in the interests of public health or safety\" (Schedule 2, Part 4 items 45–49), and the Secretary need not consider a consent application until fees are paid (Schedule 2, Part 9). These expand administrative control but also concentrate discretionary power in departmental hands, increasing scope for internal policy choices and potential administrative delay.\n\n- Market effects and private choice: Bringing vaping goods into the Therapeutic Goods Act and tightening advertising controls changes the regulatory environment for e‑cigarette products. That raises barriers for new entrants and may change marketing, packaging and pricing strategies. Pharmacy approval timing and restrictions on reapplications can affect local pharmacy competition and access to PBS supply in a locality (Schedule 1, Part 3).\n\n- Enforcement vs service delivery trade‑off: The Act prioritises enforcement tools (expanded offences, recovery powers, seizure/forfeiture and enforceable directions) and greater administrative reach. That imposes opportunity costs: resources used to investigate, litigate and enforce will not be available for other administrative tasks unless the department receives additional resourcing.\n\n- Legal and implementation risks: The Act introduces strict liability offences and broad civil penalties (Schedule 2, Part 7; Schedule 4: 129AACB). Those provisions may prompt legal challenges, disputes about retrospective effect (the Act includes some transitional saving clauses), and require clear administrative guidance to avoid inconsistent enforcement. Conditional commencement clauses (for example, some Health Insurance Act amendments commence only once an assignment‑of‑benefits measure has come into effect) add implementation complexity (Commencement table and Schedule 1, Part 1 Division 2–3).\n\n- Concentrated benefits, diffuse costs: The fiscal benefit (recoverable amounts) is concentrated in government revenue; costs are often dispersed across many small providers, manufacturers, advertisers and consumers (e.g. increased fees, compliance costs and possible price effects).\n\nKey sections to check in the Act text (examples)\n\n- Shorter claims window: Schedule 1, Part 1 (Dental Benefits Act 2008, item 1; Health Insurance Act 1973, items 3 and 7)\n- New \"relevant offence\" and data handling: Schedule 1, Part 2 (item 9 and items 11–12)\n- Pharmacist approvals: Schedule 1, Part 3 (items 16–23)\n- Vaping goods under TGA and advertising cross‑references: Schedule 2, Part 1 (multiple items) and Schedule 3, Part 1\n- New therapeutic goods offences and civil penalties: Schedule 2, Part 7 (new sections 32CP and 32CQ — item 78)\n- Chief Executive Medicare notice power and penalties for non‑compliance: Schedule 4, Part 1 (new sections 129AACA and 129AACB — item 1)\n- Recovery of overpayments as debts: Schedule 4, Part 1 (new section 129AAK — item 6)\n\nBottom line (mechanical effects): The Act tightens time limits and recovery tools for Medicare payments, expands and clarifies TGA powers (including bringing vaping goods into the TGA scheme and creating new offences/civil penalties), alters pharmacist approval procedures, and increases administrative information and enforcement powers. These changes shift legal and financial risk onto providers, suppliers and applicants, while expanding departmental discretion and enforcement capability. The official aims emphasise integrity, safety and regulatory clarity; concretely, implementation will require updated departmental processes, stakeholder compliance efforts, and close attention to transitional rules and commencement linkages."}},"importantCases":[],"_links":{"self":"/api/acts/health-legislation-amendment-improved-medicare-integrity-and-other-measures-bill-2025","history":"/api/acts/health-legislation-amendment-improved-medicare-integrity-and-other-measures-bill-2025/history","analysis":"/api/acts/health-legislation-amendment-improved-medicare-integrity-and-other-measures-bill-2025/analysis","conflicts":"/api/acts/health-legislation-amendment-improved-medicare-integrity-and-other-measures-bill-2025/conflicts","importantCases":"/api/acts/health-legislation-amendment-improved-medicare-integrity-and-other-measures-bill-2025/important-cases","documents":"/api/acts/health-legislation-amendment-improved-medicare-integrity-and-other-measures-bill-2025/documents"}}